LETTERS TO THE EDITOR
Letter to Editor
Carta al Director
Vicente Baixauli
Autor para correspondencia
mvaillo@sefac.org
Author of correspondence Vicente Baixauli, Travessera de Gracia, 56, 08006 Barcelona. Spain.
Author of correspondence Vicente Baixauli, Travessera de Gracia, 56, 08006 Barcelona. Spain.
President of the Spanish Society of Clinical, Family, and Community Pharmacy (SEFAC)
Leído
380
Vecesse ha leído el artículo
155
Total PDF
225
Total HTML
Compartir estadísticas
array:23 [ "pii" => "S113063432300168X" "issn" => "11306343" "doi" => "10.7399/fh.13188" "estado" => "S300" "fechaPublicacion" => "2022-03-01" "aid" => "168" "copyright" => "Sociedad Española de Farmacia Hospitalaria" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "cor" "cita" => "Farm Hosp. 2022;46:98-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S1130634323001691" "issn" => "11306343" "doi" => "10.7399/fh.13230" "estado" => "S300" "fechaPublicacion" => "2022-03-01" "aid" => "169" "copyright" => "Sociedad Española de Farmacia Hospitalaria" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "cor" "cita" => "Farm Hosp. 2022;46:100-1" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">LETTERS TO THE EDITOR</span>" "titulo" => "Selected evidence and cherry picking pharmaceutical compounding" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "100" "paginaFinal" => "101" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Evidencia seleccionada y cherry picking en formulación magistral" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Miguel González-Barcia, Cristina Mondelo-García, Francisco J. Otero-Espinar, Anxo Fernández-Ferreiro" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Miguel" "apellidos" => "González-Barcia" ] 1 => array:2 [ "nombre" => "Cristina" "apellidos" => "Mondelo-García" ] 2 => array:2 [ "nombre" => "Francisco J." "apellidos" => "Otero-Espinar" ] 3 => array:2 [ "nombre" => "Anxo" "apellidos" => "Fernández-Ferreiro" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1130634323001691?idApp=UINPBA00009S" "url" => "/11306343/0000004600000002/v1_202311080847/S1130634323001691/v1_202311080847/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S1130634323001678" "issn" => "11306343" "doi" => "10.7399/fh.11847" "estado" => "S300" "fechaPublicacion" => "2022-03-01" "aid" => "167" "copyright" => "Sociedad Española de Farmacia Hospitalaria" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "cor" "cita" => "Farm Hosp. 2022;46:96-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">LETTERS TO THE EDITOR</span>" "titulo" => "Atorvastatin induced rhabdomyolysis: Utility of determining genetic polymorphisms" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "96" "paginaFinal" => "97" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Rabdomiólisis por atorvastatina: Utilidad de la determinación de los polimorfismos genéticos" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Laura Villaverde Piñeiro, Andrea Pérez Castro, Beatriz Ares Castro-Conde, Ana Isabel Cachafeiro Pin" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Laura Villaverde" "apellidos" => "Piñeiro" ] 1 => array:2 [ "nombre" => "Andrea Pérez" "apellidos" => "Castro" ] 2 => array:2 [ "nombre" => "Beatriz Ares" "apellidos" => "Castro-Conde" ] 3 => array:2 [ "nombre" => "Ana Isabel Cachafeiro" "apellidos" => "Pin" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1130634323001678?idApp=UINPBA00009S" "url" => "/11306343/0000004600000002/v1_202311080847/S1130634323001678/v1_202311080847/en/main.assets" ] "en" => array:16 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">LETTERS TO THE EDITOR</span>" "titulo" => "Letter to Editor" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "98" "paginaFinal" => "99" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Vicente Baixauli" "autores" => array:1 [ 0 => array:4 [ "nombre" => "Vicente" "apellidos" => "Baixauli" "email" => array:1 [ 0 => "mvaillo@sefac.org" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor1" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "President of the Spanish Society of Clinical, Family, and Community Pharmacy (SEFAC)" "identificador" => "aff1" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "*" "correspondencia" => "<span class="elsevierStyleBold">Author of correspondence</span> Vicente Baixauli, Travessera de Gracia, 56, 08006 Barcelona. Spain." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Carta al Director" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="cesec10" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle40">To the Editor:</span><p id="para10" class="elsevierStylePara elsevierViewall">We have read with great interest the study by Calleja-Hernández <span class="elsevierStyleItalic">et al.</span><a class="elsevierStyleCrossRef" href="#bib1"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleItalic">,</span> which analyses the economic consequences of replacing the hospital pharmacy service for other dispensing scenarios in the setting of biologic treatments for psoriasis. This study showed that the least expensive scenario was dispensing in community pharmacies or in primary care. This result is in line with that obtained in the cost-minimization analysis conducted by Caballero-Romero <span class="elsevierStyleItalic">et al.</span><a class="elsevierStyleCrossRef" href="#bib2"><span class="elsevierStyleSup">2</span></a><span class="elsevierStyleItalic">.</span> These authors found that dispensing in community pharmacies had the lowest risk priority number, suggesting that this result was largely due to the role of the pharmacist regarding the custody and preservation of the drugs. It was also the least expensive option, because the cost corresponding to dispensing was not included; however, the new study<a class="elsevierStyleCrossRef" href="#bib1"><span class="elsevierStyleSup">1</span></a> included this cost<a class="elsevierStyleCrossRef" href="#bib3"><span class="elsevierStyleSup">3</span></a> and is still the least expensive option.</p><p id="para20" class="elsevierStylePara elsevierViewall">Currently, many patients have their treatments dispensed exclusively in the Hospital Pharmacy services in Spain. The COVID-19 pandemic has driven modifications to regulations on the dispensing of these drugs, and hospital pharmacists and community pharmacists have subsequently had successful collaborative experiences<a class="elsevierStyleCrossRef" href="#bib4"><span class="elsevierStyleSup">4</span></a>.</p><p id="para30" class="elsevierStylePara elsevierViewall">The Spanish Society of Clinical, Family, and Community Pharmacy (SEFAC) wishes to make further progress in this line of collaboration. From the very beginning, these patients require strict control of the pharmacological treatments dispensed in the hospital. However, from that point on, community pharmacies —through agreed protocols—can conduct adequate pharmacotherapeutic monitoring by means of continuity of care mechanisms shared between hospital and community pharmacies.</p><p id="para40" class="elsevierStylePara elsevierViewall">The results obtained so far have shown that the combination of both pharmacy professionals entails significant synergies. As President of the SEFAC, I would like to take advantage of this forum to propose to the SEFH the creation of a mixed Working Group to lay the foundation for collaborative work with the aim of ensuring the effectiveness, safety, and efficiency of prescribed hospital drugs.</p></span><span id="cesec20" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle50">Reply to letter</span><p id="para50" class="elsevierStylePara elsevierViewall">Olga Delgado Sánchez</p><p id="para60" class="elsevierStylePara elsevierViewall">Presidenta de la Sociedad Española de Farmacia Hospitalaria (SEFH).</p><p id="para70" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">To the Editor:</span></p><p id="para80" class="elsevierStylePara elsevierViewall">In relation to Dr. Baíxaull's letter referring to the work of Calleja-Hernández <span class="elsevierStyleItalic">et al</span>.<a class="elsevierStyleCrossRef" href="#bib1"><span class="elsevierStyleSup">1</span></a>, it should be noted that that this work was a modelling study of 18 theoretical scenarios, suggesting that the least expensive scenario was dispensing in Primary Care or Community Pharmacies every 12 weeks. Logically, the scenarios associated with the lowest costs are those in which administration is distributed over wider time intervals. This study was theoretical, limited to psoriasis, conducted by a consultant, and funded by a pharmaceutical laboratory.</p><p id="para90" class="elsevierStylePara elsevierViewall">Aside from this study, I believe that the role and responsibility of pharmacists is essential at all stages in the use of drugs, from evaluation and selection to monitoring effectiveness and patient safety, and that the time of dispensing is a key point of contact between pharmacists and patients.</p><p id="para100" class="elsevierStylePara elsevierViewall">During the COVID-19 pandemic, and in line with the corresponding legal changes, procedures were implemented to dispense hospital drugs closer to patients, as well as procedures involving marked changes in Hospital Pharmacy, with the implementation of non-face-to-face professional actions, telepharmacy, and deliveries to Community Pharmacies, patients’ homes, and Primary Care centres. These changes have facilitated the provision of specialized non-face-to-face care, while guaranteeing the appropriateness of treatments. The role of Community Pharmacies has also been reinforced during the pandemic, not only by providing healthcare professionals close and accessible to patients and the general population, but also due to their excellent communication work conducted with other levels of care.</p><p id="para110" class="elsevierStylePara elsevierViewall">Further progress in coordinating Hospital Pharmacy and Community Pharmacy requires profound changes between the two areas, including standardized processes, patient follow-up protocols, referral criteria, common information systems, access to clinical data on therapeutic response, and the establishment of shared and explicit therapeutic objectives for each patient.</p><p id="para120" class="elsevierStylePara elsevierViewall">As established in the regulations<a class="elsevierStyleCrossRef" href="#bib2"><span class="elsevierStyleSup">2</span></a>, Hospital Pharmacies are responsible for the pharmacotherapeutic follow-up of treated patients, and there is no doubt that pharmaceutical collaboration between Primary Care centres and Community Pharmacies is essential to achieve the required coordination and continuity of care needed for quality provision.</p><p id="para130" class="elsevierStylePara elsevierViewall">The Spanish Society of Hospital Pharmacy seeks active collaboration with all the scientific Societies involved in the use of drugs, and the Spanish Society of Community Pharmacy is key to the processes of continuity of care and pharmacotherapeutic monitoring of patients.</p><p id="para140" class="elsevierStylePara elsevierViewall">Healthcare results are consequences of the entire healthcare chain, there are no partial successes, and our capacity for improvement is determined by our ability to relate to each other.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:4 [ 0 => array:2 [ "identificador" => "cesec10" "titulo" => "To the Editor:" ] 1 => array:2 [ "identificador" => "cesec20" "titulo" => "Reply to letter" ] 2 => array:1 [ "titulo" => "<span class="elsevierStyleSectionTitle" id="cesectitle10">Uncited references</span>" ] 3 => array:1 [ "titulo" => "Bibliography" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2021-12-21" "fechaAceptado" => "2022-02-16" "NotaPie" => array:1 [ 0 => array:1 [ "nota" => "<p class="elsevierStyleNotepara" id="cenpara10">Early Access date (03/10/2022).</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "cebibsec10" "bibliografiaReferencia" => array:4 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tratamientos biológicos para la psoriasis: coste de los métodos alternativos de dispensación de la medicación en España" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ Calleja-Hernández MA \n \t\t\t\t\t\t\t\t """ 1 => """ Ventayol-Bosch P \n \t\t\t\t\t\t\t\t """ 2 => """ Martí-Ragué I \n \t\t\t\t\t\t\t\t """ 3 => """ Casañas-Domingo M \n \t\t\t\t\t\t\t\t """ 4 => """ Costa-Samarra J \n \t\t\t\t\t\t\t\t """ 5 => """ Nieves-Calatrava D \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Farm Hosp." "fecha" => "2021" "volumen" => "45" "numero" => "6" "paginaInicial" => "323" "paginaFinal" => "381" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34806572" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Análisis modal de fallos y efectos y análisis de minimización de costes de tres programas de entrega de medicamentos" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ Caballero-Romero A \n \t\t\t\t\t\t\t\t """ 1 => """ Fernández S \n \t\t\t\t\t\t\t\t """ 2 => """ Morillo AB \n \t\t\t\t\t\t\t\t """ 3 => """ Zaragoza-Rascón M \n \t\t\t\t\t\t\t\t """ 4 => """ Jarami-lo-Pérez C \n \t\t\t\t\t\t\t\t """ 5 => """ Del Pozo-Rubio R \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7399/fh.11532" "Revista" => array:7 [ "tituloSerie" => "Farm Hosp." "fecha" => "2021" "volumen" => "45" "numero" => "2" "paginaInicial" => "66" "paginaFinal" => "72" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33709888" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Sanz Granda Á. Estudio del coste de la dispensación de la farmacia comunitaria en España [Internet]. España: Sociedad Española de Farmacia Comunitaria (SEFAC). 2012 [accessed 26/05/2020]. Available at: <a target="_blank" href="https://www.sefac.org/sites/default/files/sefac2010/documentos_sefac/documentos/Coste_de_dispensacion_%20Espana_Res_Ejecutivo.pdf">https://www.sefac.org/sites/default/files/sefac2010/documentos_sefac/documentos/Coste_de_dispensacion_%20Espana_Res_Ejecutivo.pdf</a>" ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "HIRIS. Estudio y valoración de experiencias de dispensación colaborativa de medicamentos de Diagnóstico Hospitalario y Dispensación Hospitalaria (DHDH) durante la COVID-19 [Internet]. Consejo General de Colegios Oficiales de Farmacéuticos de España; 2021 [accessed 13/12/2021]. Available at: INFORME-HIRIS-20-07-2021.pdf (farmaceuticos.com)" ] ] ] ] ] ] ] "lecturaRecomendada" => array:1 [ 0 => array:3 [ "vista" => "all" "titulo" => "<span class="elsevierStyleSectionTitle" id="cesectitle10">Uncited references</span>" "seccion" => array:1 [ 0 => array:2 [ "vista" => "all" "bibliografiaReferencia" => array:2 [ 0 => array:3 [ "identificador" => "bib5" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tratamientos biológicos para la psoriasis: coste de los métodos alternativos de dispensación de la medicación en España" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ Calleja-Hernández MA \n \t\t\t\t\t\t\t\t """ 1 => """ Ventayol-Bosch P \n \t\t\t\t\t\t\t\t """ 2 => """ Martí-Ragué I \n \t\t\t\t\t\t\t\t """ 3 => """ Casañas-Domingo M \n \t\t\t\t\t\t\t\t """ 4 => """ Costa-Samarra J \n \t\t\t\t\t\t\t\t """ 5 => """ Nieves-Calatrava D \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Farm Hosp." "fecha" => "2021" "volumen" => "45" "numero" => "6" "paginaInicial" => "323" "paginaFinal" => "381" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib6" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Real Decreto-Ley 21/2020, de 9 de junio, de medidas urgentes de prevención, contención y coordinación para hacer frente a la crisis sanitaria ocasionada por el COVID-19" ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/11306343/0000004600000002/v1_202311080847/S113063432300168X/v1_202311080847/en/main.assets" "Apartado" => array:4 [ "identificador" => "8903" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Cartas al Director" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/11306343/0000004600000002/v1_202311080847/S113063432300168X/v1_202311080847/en/main.pdf?idApp=UINPBA00009S&text.app=https://www.revistafarmaciahospitalaria.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S113063432300168X?idApp=UINPBA00009S" ]
Información del artículo
ISSN: 11306343Idioma original: Inglés
DOI:10.7399/fh.13188
Datos actualizados diariamente
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 0 | 2 | 2 |
| 2024 Octubre | 17 | 8 | 25 |
| 2024 Septiembre | 23 | 16 | 39 |
| 2024 Agosto | 20 | 18 | 38 |
| 2024 Julio | 17 | 18 | 35 |
| 2024 Junio | 20 | 15 | 35 |
| 2024 Mayo | 31 | 18 | 49 |
| 2024 Abril | 19 | 12 | 31 |
| 2024 Marzo | 17 | 8 | 25 |
| 2024 Febrero | 13 | 12 | 25 |
| 2024 Enero | 18 | 11 | 29 |
| 2023 Diciembre | 18 | 2 | 20 |
| 2023 Noviembre | 12 | 15 | 27 |
Mostrar todo
